Celcuity Launches REVTORPYK Commercially in the U.S. for HR+/HER2- Advanced Breast Cancer
CELC sits 78% above its 52-week low of $44.42.
Summary
Celcuity announced that REVTORPYK (gedatolisib) is now commercially available in the U.S. for eligible patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation, marking the company's first commercial product launch.
Key Events · Product Development and Regulatory · CELC
-
REVTORPYK Commercial Launch
REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer without a PIK3CA mutation, following FDA approval on July 14, 2026.
-
First Commercial Product
This is Celcuity's first FDA-approved and commercially available product, transitioning the company from clinical-stage to commercial-stage.
-
Patient Support Program Launched
REVTORPYK Support Services program launched to provide financial assistance, insurance coverage support, and treatment enrollment resources for physicians and eligible patients.
-
Clinical Differentiation
REVTORPYK is the first and only FDA-approved therapy inhibiting all class I PI3K isoforms and mTORC1/mTORC2, with Phase 3 data showing 76% and 67% risk reduction for triplet and doublet regimens respectively.
Analysis · CELC · Industrial Applications And Services
REVTORPYK, Celcuity's first FDA-approved drug, is now commercially available in the United States. This marks the company's transition from clinical-stage to commercial-stage, with revenue generation now possible. The launch follows the July 14, 2026 FDA approval and includes a patient support program to facilitate access and reimbursement. For a company with a $3.8 billion market cap and $754 million in cash, successful commercialization is the key milestone investors have been waiting for.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELC was trading at $79.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $44.42 to $151.02. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.